Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.

In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.

By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.

Depending on the pMDI/spacer system chosen the delivery of medication can vary significantly and as a result will have implications on the potential carbon footprint.

In this case, the use of the AeroChamber Plus* Flow-Vu* VHC could potentially reduce the carbon footprint by three fold compared to the alternative spacers.

By maximizing the amount of each puff reaching the lungs the patient is likely to be able to get relief sooner and reduce the amount of puffs needed.

Do you use a puffer to manage your asthma or other respiratory condition? If so, you may have heard about using a spacer with your puffer. But what is a spacer and how does it work? This article explores the benefits of using a spacer with your puffer and provides tips on how to use one properly. Whether you're new to using a spacer or just looking to improve your technique, this article has you covered.

Do you use a puffer to manage your asthma or other respiratory condition? If so, you may have heard about using a spacer with your puffer. But what is a spacer and how does it work? This article explores the benefits of using a spacer with your puffer and provides tips on how to use one properly. Whether you're new to using a spacer or just looking to improve your technique, this article has you covered.

• The FRI deposition profiles highlight that the MDI/AeroChamber Plus* Flow-Vu* VHC delivered a significantly greater percentage of drug to the lung region than either of the two DPIs, irrespective of flow rate.
• This was reflected in much higher modelled oropharyngeal deposition for the two DPIs.
• The influence of inhalation flow profile was significant for one of the DPIs.

This study was presented at the Drug Delivery to the Lungs Conference, 2022.

As current MDIs contain hydrofluorocarbon propellants, it would be beneficial to find ways to reduce carbon emissions without compromising patient safety.

This lab study investigated a way to optimize the modelled lung dose per actuation while at the same time minimizing the carbon emissions from the MDI